** Amgen AMGN.O said on Thursday its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to speculate on the impact of U.S. tariffs, tax policy would be a more effective way to influence U.S. manufacturing
** Median PT of brokerages covering the stock is $315.46 - data compiled by LSEG
FOCUS REMAINS ON MARITIDE
** Mizuho ("Neutral", PT: $235) believes many questions remain unanswered on experimental weight-loss drug MariTide, viewed by many investors as a potential blockbuster
** J.P.Morgan ("Neutral", PT: $283.78) expects shares to "remain range bound pending longer-term obesity updates for MariTide"
** RBC Capital Markets ("Outperform", PT: $320) believes greater visibility into critical inflection points for Horizon-derived products in the rare disease space, like thyroid eye disease drug Tepezza, gout treatment Krystexxa, and immune disorder drug Uplizna is necessary to bolster investor confidence
** Piper Sandler ("Overweight", PT: $329) says Amgen's strategy of launching new biosimilars will help in "cushioning the impact" by offsetting the revenue loss from products losing their patent protection
** Citi ("Neutral", PT: $300) says they are positive of AMGN's rare product portfolio from the Horizon acquisition
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。